FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies

Roche announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair ® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news